Utility of carboplatin therapeutic drug monitoring for the treatment of neonate and infant retinoblastoma patients in the United Kingdom.

Gerard Cathal MillenAlice LawfordCatriona DuncanHelen JenkinsonGareth J VealShelby Barnett

Published in: British journal of cancer (2024)

Real time TDM is safe, effective and deliverable for neonates and infants receiving carboplatin for retinoblastoma and should be considered standard of care up to the age of 6 months.

Keyphrases

end stage renal disease
ejection fraction
healthcare
chronic kidney disease
newly diagnosed
phase ii study
palliative care
peritoneal dialysis
prognostic factors
squamous cell carcinoma
randomized controlled trial
cross sectional
phase iii
low birth weight
study protocol
preterm birth